Latanea (Latanoprost)

Latanoprost mimics prostaglandin F₂α and binds to FP receptors in the ciliary body. This triggers remodeling of extracellular matrix proteins, which enhances the uveoscleral outflow pathway for aqueous humor. The increased outflow lowers intra‑ocular pressure, providing therapeutic benefit in glaucoma and ocular hypertension.

The prescribed dose of latanoprost is determined by the treating ophthalmologist. Typically, one drop of the ophthalmic solution is instilled into the affected eye(s) once daily, usually in the evening, but the exact regimen should follow the prescriber’s instructions.

Safety of latanoprost in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order Latanea, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Latanoprost is often preferred for its once‑daily dosing and strong intra‑ocular pressure‑lowering effect. Compared with beta‑blockers, it has fewer systemic cardiovascular effects; versus carbonic anhydrase inhibitors, it avoids taste disturbances. However, prostaglandin analogs can cause ocular pigmentation changes, which are less common with other classes.

Latanea should be stored at room temperature below 25 °C, in its original container, protected from light and moisture. Do not freeze the product. Keep the bottle tightly closed when not in use and avoid contaminating the tip of the dropper.

Latanea is an ophthalmic solution. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place one drop into the conjunctival sac without touching the tip to the eye or lashes. Close the eye gently for a few minutes and avoid blinking excessively.

Serious but rare risks include uveitis or iritis, macular edema, formation of iris or retinal cysts, and severe allergic reactions such as swelling or rash around the eye. If any of these occur, the patient should discontinue use and seek immediate ophthalmologic evaluation.

Latanea should not be used by individuals with known hypersensitivity to latanoprost or any excipients, or by patients with active ocular infections or inflammation until these conditions are resolved. Caution is also advised for patients with a history of herpetic keratitis or severe ocular surface disease.